ArticleCVIR endovascular2026
Outcomes of Castor single-branched stent graft combined with in situ fenestration left subclavian artery in aortic arch disease: a single-center experience.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo evaluate outcomes of Castor single-branched stent graft combined with in situ fenestration of the left subclavian artery for aortic arch disease.
methodsA retrospective analysis of 30 patients undergoing TEVAR with Castor stent that was first implanted with the branch in the left common carotid artery (LCCA) followed by in situ fenestration of the left subclavian (LSA) between March 2022 and March 2024 was conducted. Perioperative and follow-up data were collected and analyzed.
resultsThe study retrospective analysis of 30 patients comprised 16 (53.3%) with acute type B aortic dissections, 6 (20%) with thoracic aortic aneurysms, 2 (6.7%) with intramural hematoma, and 6 (20%) with penetrating aortic ulceration. The technical success rate was 96.7% (29/30). One patient required carotid-axillary bypass due to subclavian artery lateral wall opening. There were no cases of mortality, stroke, upper limb ischemia, paraplegia, or stent graft-induced new entry within the 30-day follow-up period. Median hospitalization was 11 (IQR, 9-14) days, with a median follow-up of 12 (IQR, 8-19) months. One patient (3.3%) suffered a fall-related cerebral hemorrhage unrelated to the procedure. Another (3.3%) developed left upper limb ischemia due to stent angulation, corrected with a cover stent. Subclavian artery patency was 96.6% (28/29), and carotid artery patency was 100%. No deaths, endoleaks, or stent migrations occurred.
conclusionThe Castor stent combined with in situ fenestration is a feasible, effective, and safe strategy for aortic arch disease repair, especially in providing alternative approaches for aortic diseases that require reconstruction in both branches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.